AEVI-001

DRUG2 trials

Sponsors

Aevi Genomic Medicine, LLC, a Cerecor company

Conditions

Attention Deficit Hyperactivity Disorder

Phase 2

PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations

CompletedNCT03265119

Aevi Genomic Medicine, LLC, a Cerecor companyAttention Deficit Hyperactivity Disorder

Start: 2017-08-28End: 2018-10-01Updated: 2021-07-07

PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations

CompletedNCT03609619

Aevi Genomic Medicine, LLC, a Cerecor companyAttention Deficit Hyperactivity Disorder

Start: 2018-08-17End: 2018-11-30Updated: 2021-07-30